(Q43201721)

16 November 2017

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test (English)

1 reference

16 November 2017

Llerena A

4

0 references

author name string

Bertilsson L

1

1 reference

16 November 2017

Carrillo JA

2

1 reference

16 November 2017

Dahl ML

3

1 reference

16 November 2017

Alm C

5

1 reference

16 November 2017

Bondesson U

6

1 reference

16 November 2017

Lindström L

7

1 reference

16 November 2017

Rodriguez de la Rubia I

8

1 reference

16 November 2017

Ramos S

9

1 reference

16 November 2017

Benitez J

10

1 reference

16 November 2017

language of work or name

English

0 references

publication date

1 November 1994

1 reference

British Journal of Clinical Pharmacology

16 November 2017

1 reference

16 November 2017

38

1 reference

16 November 2017

471-473

1 reference

16 November 2017

5

1 reference

The use of caffeine for enzyme assays: a critical appraisal

16 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1364883

Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1364883

Genetically variable metabolism of antidepressants and neuroleptic drugs in man.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1364883

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1364883

Clozapine. A novel antipsychotic agent

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1364883

Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1364883

The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1364883

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1364883

3 November 2018

1 reference

12 December 2020

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

1 reference

12 December 2020

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1 reference

12 December 2020

Fluvoxamine-tricyclic antidepressant interaction

1 reference

12 December 2020

Interaction between fluvoxamine and imipramine/desipramine in four patients

1 reference

12 December 2020

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

12 December 2020

Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects

1 reference

12 December 2020

Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways

1 reference

12 December 2020

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

12 December 2020

Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism

1 reference

12 December 2020

10.1111/J.1365-2125.1994.TB04385.X

Identifiers

DOI

1 reference

16 November 2017

1 reference

16 November 2017

1 reference